FDA panel backs Acadia drug for psychosis linked to Parkinson's

FDA panel backs Acadia drug for psychosis linked to Parkinson's
(Reuters) – An advisory panel to the U.S. Food and Drug Administration backed an approval for Acadia Pharmaceuticals Inc’s drug for psychosis related to Parkinson’s disease.



Source

Comments are closed.